SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery
Sodium-glucose cotransporter-2 SGLT2 inhibitors are antihyperglycemic drugs that are currently being recommended as second-line therapy for patients with diabetes mellitus. They have grown increasingly popular over recent years, as they have been shown to have some protective effects on the heart an...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Critical Care |
| Online Access: | http://dx.doi.org/10.1155/2020/8817829 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560236347523072 |
|---|---|
| author | Qasim Zafar Iqbal Danil Mishiyev Muhammad Raphay Niazi Zeeshan Zia Saud Bin Abdul Sattar Abdullah Jahanghir Shahed Quyyumi |
| author_facet | Qasim Zafar Iqbal Danil Mishiyev Muhammad Raphay Niazi Zeeshan Zia Saud Bin Abdul Sattar Abdullah Jahanghir Shahed Quyyumi |
| author_sort | Qasim Zafar Iqbal |
| collection | DOAJ |
| description | Sodium-glucose cotransporter-2 SGLT2 inhibitors are antihyperglycemic drugs that are currently being recommended as second-line therapy for patients with diabetes mellitus. They have grown increasingly popular over recent years, as they have been shown to have some protective effects on the heart and kidneys, both organ systems that diabetes mellitus has shown to have deleterious effect on over time. Despite their growing popularity, they have been found to increase the risk of euglycemic diabetic ketoacidosis (DKA). There is an increasing body of literature detailing cases of euglycemic DKA after bariatric surgery. We present a case series of three cases of euglycemic DKA postbariatric surgery in patients with an underlying history of type 2 diabetes mellitus, who were being treated with SGLT2 inhibitors prior to the surgery. All three patients reported to the emergency room with signs, symptoms, and clinical findings of euglycemic DKA. The AACE recommends SGLT2 inhibitors to be discontinued at least 24 hours prior to surgery and resumed when a patient resumes a normal diet. Our patients presented with euglycemic DKA after bariatric surgery, and we recommend more research should be done targeted at the prolonged postoperative course of patients on SGLT-2 inhibitors and into creating specific guidelines for their use after bariatric surgery. |
| format | Article |
| id | doaj-art-380f4a09ec57479c855d110d61aa29d4 |
| institution | Kabale University |
| issn | 2090-6420 2090-6439 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Critical Care |
| spelling | doaj-art-380f4a09ec57479c855d110d61aa29d42025-02-03T01:28:07ZengWileyCase Reports in Critical Care2090-64202090-64392020-01-01202010.1155/2020/88178298817829SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric SurgeryQasim Zafar Iqbal0Danil Mishiyev1Muhammad Raphay Niazi2Zeeshan Zia3Saud Bin Abdul Sattar4Abdullah Jahanghir5Shahed Quyyumi6Staten Island University Hospital, Northwell, USAStaten Island University Hospital, Northwell, USAStaten Island University Hospital, Northwell, USAStaten Island University Hospital, Northwell, USAStaten Island University Hospital, Northwell, USAStaten Island University Hospital, Northwell, USAStaten Island University Hospital, Northwell, USASodium-glucose cotransporter-2 SGLT2 inhibitors are antihyperglycemic drugs that are currently being recommended as second-line therapy for patients with diabetes mellitus. They have grown increasingly popular over recent years, as they have been shown to have some protective effects on the heart and kidneys, both organ systems that diabetes mellitus has shown to have deleterious effect on over time. Despite their growing popularity, they have been found to increase the risk of euglycemic diabetic ketoacidosis (DKA). There is an increasing body of literature detailing cases of euglycemic DKA after bariatric surgery. We present a case series of three cases of euglycemic DKA postbariatric surgery in patients with an underlying history of type 2 diabetes mellitus, who were being treated with SGLT2 inhibitors prior to the surgery. All three patients reported to the emergency room with signs, symptoms, and clinical findings of euglycemic DKA. The AACE recommends SGLT2 inhibitors to be discontinued at least 24 hours prior to surgery and resumed when a patient resumes a normal diet. Our patients presented with euglycemic DKA after bariatric surgery, and we recommend more research should be done targeted at the prolonged postoperative course of patients on SGLT-2 inhibitors and into creating specific guidelines for their use after bariatric surgery.http://dx.doi.org/10.1155/2020/8817829 |
| spellingShingle | Qasim Zafar Iqbal Danil Mishiyev Muhammad Raphay Niazi Zeeshan Zia Saud Bin Abdul Sattar Abdullah Jahanghir Shahed Quyyumi SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery Case Reports in Critical Care |
| title | SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery |
| title_full | SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery |
| title_fullStr | SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery |
| title_full_unstemmed | SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery |
| title_short | SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery |
| title_sort | sglt 2 inhibitors a culprit of diabetic ketoacidosis postbariatric surgery |
| url | http://dx.doi.org/10.1155/2020/8817829 |
| work_keys_str_mv | AT qasimzafariqbal sglt2inhibitorsaculpritofdiabeticketoacidosispostbariatricsurgery AT danilmishiyev sglt2inhibitorsaculpritofdiabeticketoacidosispostbariatricsurgery AT muhammadraphayniazi sglt2inhibitorsaculpritofdiabeticketoacidosispostbariatricsurgery AT zeeshanzia sglt2inhibitorsaculpritofdiabeticketoacidosispostbariatricsurgery AT saudbinabdulsattar sglt2inhibitorsaculpritofdiabeticketoacidosispostbariatricsurgery AT abdullahjahanghir sglt2inhibitorsaculpritofdiabeticketoacidosispostbariatricsurgery AT shahedquyyumi sglt2inhibitorsaculpritofdiabeticketoacidosispostbariatricsurgery |